AstraZeneca's Breztri Approved in the U.S. for Asthma Treatment
AstraZeneca's Breztri Aerosphere has received U.S. approval for the maintenance treatment of asthma in adults and pediatric patients aged 12 and older. The fixed-dose triple-combination therapy is delivered via a single inhaler. This approval expands the drug's market reach and may impact AstraZeneca's revenue.
Tickers: $AZN
Topics: asthma treatment AstraZeneca pharmaceuticals regulatory approval